Spatially resolved metabolic phenotyping of breast cancer by desorption electrospray ionization mass spectrometry

Cancer Research

Volumn 75, Issue 9, 2015, Pages 1828-1837

  Guenther, Sabine ^a   Muirhead, Laura J ^a   Speller, Abigail V M ^a   Golf, Ottmar ^a   Strittmatter, Nicole ^a   Ramakrishnan, Rathi ^a   Goldin, Robert D ^a   Jones, Emrys ^a   Veselkov, Kirill ^a   Nicholson, Jeremy ^a   Darzi, Ara ^a   Takats, Zoltan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HORMONE RECEPTOR; PHOSPHOLIPID;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIPID COMPOSITION; LIPOGENESIS; METABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE SPECIFICITY; TUMOR MICROENVIRONMENT; BREAST TUMOR; CHEMISTRY; DIAGNOSTIC IMAGING; METABOLISM; METABOLOME; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FATTY ACIDS; FEMALE; HUMANS; METABOLOME; MIDDLE AGED; PHENOTYPE; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; YOUNG ADULT;

EID: 84938623834     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2258     Document Type: Article

References (48)

1. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
2. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX (TM) Recurrence Score. Mod Pathol 2008;21:1255-61.
3. Mook S, Van't Veer LJ, Rutgers EJT, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genom Proteomics 2007;4:147-55.
4. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol 2009;27:1160-67.
5. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-78.
6. Bartlett JMS, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, et al. Mammostrat (R) as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47.
7. Heaphy CM, BisoffiM, Fordyce CA, Haaland CM, Hines WC, Joste NE, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2006;119:108-16.
8. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Phung V, et al. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2011;129:1310-21.
9. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
10. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 2009; 118:229-39.
11. Roman-Perez E, Casbas-Hernandez P, Pirone JR, Rein J, Carey LA, Lubet RA, et al. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 2012;14: R51.
12. Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen Y-Y, Hsu H, et al. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol 2011;3:490-96.
13. Gode D, Volmer DA. Lipid imaging by mass spectrometry - a review. Analyst 2013;138:1289-315.
14. McDonnell LA, Heeren RMA. Imaging mass spectrometry. Mass Spectrom Rev 2007;26:606-43.
15. Chaurand P. Imagingmass spectrometry of thin tissue sections: a decade of collective efforts. J Proteomics 2012;75:4883-92.
16. Seeley EH, Caprioli RM. Imaging mass spectrometry: towards clinical diagnostics. Proteomics Clin Appl 2008;2:1435-43.
17. Seeley EH, Caprioli RM. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol 2011;29:136-43.
18. Schoene C, Hoefler H, Walch A. MALDI imaging mass spectrometry in cancer research: Combining proteomic profiling and histological evaluation. Clin Biochem 2013;46:539-45.
19. Dill AL, Ifa DR, Manicke NE, Zheng O, Cooks RG. Mass spectrometric imaging of lipids using desorption electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:2883-89.
20. Eberlin LS, Ferreira CR, Dill AL, Ifa DR, Cooks RG. Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 2011;1811:946-60.
21. Eberlin LS, Norton I, Orringer D, Dunn IF, Liu X, Ide JL, et al. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci 2013;110:1611-16.
22. Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci USA 2014;111:11121-26.
23. Calligaris D, CaragacianuD, Liu X, Norton I, Thompson CJ, Richardson AL, et al. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl Acad Sci 2014;111: 15184-89.
24. Schramm T, Hester A, Klinkert I, Both JP, Heeren RMA, Brunelle A, et al. imzML-A common data format for the flexible exchange and processing of mass spectrometry imaging data. J Proteomics 2012;75:5106-10.
25. Alexandrov T. MALDI imaging mass spectrometry: statistical data analysis and current computational challenges. Bmc Bioinformatics 2012; 13:S11.
26. Veselkov KA, Mirnezami R, Strittmatter N, Goldin RD, Kinross J, Speller AVM, et al. Chemo-informatic strategy for imaging mass spectrometrybased hyperspectral profiling of lipid signatures in colorectal cancer. Proc Natl Acad Sci USA 2014;111:1216-21.
27. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, et al. METLIN - A metabolite mass spectral database. Ther Drug Monit 2005;27: 747-51.
28. Schmelzer K, Fahy E, Subramaniam S, Dennis EA. The lipid maps initiative in lipidomics. Lipidomics and Bioactive Lipids: Mass-Spectrometry-Based Lipid Analysis 2007;432:171-83.
29. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Res 2013;41: D801-D07.
30. Hilvo M, Denkert C, Lehtinen L, Mueller B, Brockmoeller S, Seppanen-Laakso T, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011;71:3236-45.
31. Sakai K, Okuyama H, Yura J, Takeyama H, Shinagawa N, Tsuruga N, et al. Composition and turnover of phospholipids and neutral lipids in human breast-cancer and reference tissues. Carcinogenesis 1992;13: 579-84.
32. Hvidberg E, Langgard H, Jensenholm J. Sodium, potassium and chloride in connective tissue. Acta Pharmacologica Et Toxicologica 1963;20:131-9.
33. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
34. Beckonert O, Monnerjahn K, Bonk U, Leibfritz D. Visualizing metabolic changes in breast-cancer tissue using H-1-NMR spectroscopy and selforganizing maps. Nmr in Biomedicine 2003;16:1-11.
35. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
36. Gray J, Druker B. Genomics - The breast cancer landscape. Nature 2012;486:328-29.
37. Goncalves A, Bertucci F. Clinical Application of Proteomics in Breast Cancer: State of the Art and Perspectives. Med Princ Pract 2011;20:4-18.
38. Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers. Cancer Res 2012;72:2428-39.
39. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: Available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-46.
40. Denkert C, Bucher E, Hilvo M, Salek R, Oresic M, Griffin J, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med 2012;4:37.
41. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-99.
42. Sampaio JL, Gerl MJ, Klose C, Ejsing CS, Beug H, Simons K, et al. Membrane lipidome of an epithelial cell line. Proc Natl Acad Sci USA 2011;108:1903-07.
43. Punnonen K, Hietanen E, Auvinen O, Punnonen R. Phospholipids and fattyacids in breast-cancer tissue. J Cancer Res Clin Oncol 1989;115:575-78.
44. Byun JS, Gardner K. Wounds That Will Not Heal Pervasive Cellular Reprogramming in Cancer. Am J Pathol 2013;182:1055-64.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-67.
46. Conklin MW, Keely PJ. Why the stroma matters in breast cancer Insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr 2012;6:249-60.
47. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012;31:195-208.
48. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8:3984-4001.